Core Insights - Vertex Pharmaceuticals announced positive Week 36 interim analysis results from the RAINIER Phase 3 trial of povetacicept for IgA nephropathy, achieving significant reductions in proteinuria and serum Gd-IgA1 levels compared to placebo [1][2][3] Efficacy Results - The primary endpoint showed a 52.0% reduction in proteinuria (UPCR) from baseline, with a statistically significant 49.8% reduction compared to placebo (P<0.0001) [1][2] - For the first secondary endpoint, povetacicept treatment resulted in a 77.4% reduction in serum Gd-IgA1, leading to a 79.3% reduction compared to placebo (P<0.0001) [1][2] - In patients with baseline hematuria, 85.1% achieved hematuria resolution, a 61.7% improvement compared to placebo (P<0.0001) [1][2] Safety Profile - Povetacicept was generally safe and well tolerated, with most adverse events being mild to moderate [1][2] - Serious adverse events were low, with 3.0% in the povetacicept group and 4.3% in the placebo group [2] - Treatment discontinuation rates were 3.8% for povetacicept and 8.8% for placebo [1][2] Regulatory and Development Plans - Vertex plans to complete the Biologics License Application (BLA) for povetacicept by the end of March for potential U.S. Accelerated Approval [1][2] - The FDA has granted rolling review for the BLA, which Vertex is expediting using a priority review voucher [2][3] - The RAINIER trial will continue with final analysis expected at two years of treatment, focusing on total estimated glomerular filtration rate (eGFR) slope [2][3] About Povetacicept - Povetacicept is a dual inhibitor of BAFF and APRIL cytokines, showing improved binding affinity and potency compared to other inhibitors in preclinical studies [2][3] - It has received FDA Breakthrough Therapy Designation for IgA nephropathy and is the only dual BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases [2][3] About IgA Nephropathy - IgA nephropathy is a serious kidney disease affecting approximately 330,000 people in the U.S. and Europe, with a significant risk of progression to end-stage renal disease [2][3]

Core Insights - Vertex Pharmaceuticals announced positive data from a Phase 4 study of JOURNAVX® (suzetrigine), a non-opioid pain signal inhibitor for treating moderate-to-severe acute pain in adults [1] - The study demonstrated effective pain management and facilitated opioid-free recovery following various plastic surgical procedures [1] - A significant finding was that 90.9% of patients in the study remained opioid-free by the end of treatment [1]